Advertisement
Canada markets closed
  • S&P/TSX

    21,217.53
    -38.08 (-0.18%)
     
  • S&P 500

    4,975.51
    -30.06 (-0.60%)
     
  • DOW

    38,563.80
    -64.19 (-0.17%)
     
  • CAD/USD

    0.7396
    -0.0018 (-0.25%)
     
  • CRUDE OIL

    78.27
    -0.92 (-1.16%)
     
  • Bitcoin CAD

    70,421.70
    +231.23 (+0.33%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,035.40
    +11.30 (+0.56%)
     
  • RUSSELL 2000

    2,004.14
    -28.60 (-1.41%)
     
  • 10-Yr Bond

    4.2750
    -0.0200 (-0.47%)
     
  • NASDAQ futures

    17,592.25
    -151.75 (-0.86%)
     
  • VOLATILITY

    15.42
    +0.71 (+4.83%)
     
  • FTSE

    7,719.21
    -9.29 (-0.12%)
     
  • NIKKEI 225

    38,363.61
    -106.77 (-0.28%)
     
  • CAD/EUR

    0.6840
    -0.0034 (-0.49%)
     

Stocks in play: Sernova Corp.

Announced today that significant progress has been achieved in its collaboration with Evotec SE. This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024. The objective of the collaboration is to produce an off-the-shelf, commercially viable, ethically derived cell therapy treatment for people suffering from T1D. The treatment would include Sernova’s Cell Pouch System™ incorporating Evotec’s iPSC-derived islet-like clusters. The combination product is anticipated to be the first treatment of its kind to reach clinical testing for T1D. Sernova Corp. shares T.SVA are trading unchanged at $0.93.

Read: